Separation and formulation of bioactive fraction and subfraction from camel urine work as anticancer agent

Abstract

A pharmaceutical composition includes an effective amount of bio-active fraction PMF or subfraction PMFK obtained from the lyophilized camel urine or cow urine which coded in publications with PM701, that is used as anti-cancer drug selected from an anticancer compound PM701, which are targeted selectively the cancer cells without affecting the normal cells.

1 . A novel use of camel urine coded as PM701 as an anti-cancer agent. 
   
   
       2 . A pharmaceutical composition comprising:
 at least one anticancer agent, and   a camel urine lyophilized or a dried fractions (PMF and PMFK) obtained from camel urine lyophilized.   
   
   
       3 . The composition of  claim 2 , wherein said camel urine is the adult single-humped Arabian camel  Camelus dromedarius.    
   
   
       4 . The composition of  claim 2 , wherein the composition is obtained in a powder form by the lyophilization of PM701 in the range of 20 g for each 100 ml of fresh liquid PM701. 
   
   
       5 . The composition of  claim 4 , comprising the following physical characteristics: a yellowish color, a solid crystalline form, a sharp (offensive) odor, a pH is 8.3, water insoluble and a specific gravity of 1.045. 
   
   
       6 . The composition of  claim 4  wherein the composition exhibits a target selective anti-cancer effect in causing antiproliferative and apoptotic activities in vitro on diverse cancer tissues representing two different types of cancers (human lung cells (A549) and mice leukemic cells (L1210)) and nourishing effects on human normal tissues of human foreskin and vero cells. 
   
   
       7 . The composition of  claim 4 , wherein the composition is fractionated by a number of trials in order to isolate the most effective bio-active fraction (PMF) through the bio-guided fractionation. 
   
   
       8 . The composition of  claim 7  obtained by fractionation in the range 150 mg/g of lyophilized PM701 . 
   
   
       9 . The composition of  claim 7 , wherein the fraction isolated from the lyophilized PM701 is subjected for further subfractionation in solvent systems each 250 ml consisting essentially of chloroform and methanol to obtain seven subfractions, with a most effective subfraction being called PMFK. 
   
   
       10 . The composition of  claim 9  obtained by subfractionation in the range 108.7 mg/g of PMF. 
   
   
       11 . The composition of  claim 10  comprising about 108.7 mg/g of the composition including about 150 mg/g of lyophilized PM701. 
   
   
       12 . The composition of  claim 7 , wherein concentration effects on the cell viability and proliferation of the cancer cells was at concentrations in the range of 80 μg and 800 μg. 
   
   
       13 . The composition of  claim 9 , wherein concentration effects on the cell viability and proliferation of the cancer cells was at concentrations in the range of 0.2 μg and 2 μg. 
   
   
       14 . The composition of  claim 7 , comprising an effective amount of the composition in the amount of 435 mg/capsule with 7 capsules/day. 
   
   
       15 . The composition of  claim 9 , comprising an effective amount of the composition in the amount of 435 mg/capsule with 5 capsules/day. 
   
   
       16 . The composition of  claim 2 , wherein the dried PM 701 of the camel urine lyophilized can be obtained by distillation. 
   
   
       17 . The composition of  claim 7 , wherein the dried fractions (PMF and PMFK) obtained from the camel urine lyophilized are devoid of a camel urine smell. 
   
   
       18 . The composition of  claim 9 , wherein the dried fractions (PMF and PMFK) obtained from the camel urine lyophilized are devoid of a camel urine smell. 
   
   
       19 . A pharmaceutical composition comprising:
 a least one anticancer agent; and   a cow urine distillate or a dried fraction (GM-IV) obtained from cow urine distillate.   
   
   
       20 . The pharmaceutical composition of  claim 19 , wherein the cow urine distillate is present in a concentration range of 0.001 pl/ml to 100 pl/ml. 
   
   
       21 . The pharmaceutical composition of  claim 19 , further comprising Taxol. 
   
   
       22 . The pharmaceutical composition of  claim 19 , wherein the dried fraction (GM-IV) of the cow urine distillate is obtained by lyophilization. 
   
   
       23 . The composition of  claim 22 , wherein the dried fraction (GM-IV) obtained from the cow urine distillate has the following physical characteristics: a white color, a solid crystalline form, water solubility, a melting point above 400° C., a specific gravity of 1.006 and an RF value in methanol: chloroform (50:50) phase 0.65. 
   
   
       24 . The composition of  claim 22 , wherein the dried fraction (GM-IV) obtained from the cow urine distillate is devoid of a cow urine smell.